SecBot SecBot
8-K ·Filed Jul 21, 2026

ZEOX

Zeo ScientifiX, Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed3mo ago SEC0001829126-26-007689
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

No immediate trading catalyst — the press release is a general ecosystem positioning update without new financials or milestones. Monitor upcoming quarterly filings for revenue progress and clinical developments.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
ZEOX ▼ -31.95% at T+60d
NEUTRAL call -31.95% · α vs SPY -36.20% · entry $1.69 → $1.15
Entry = T+0 close
Jul 21, 2026
via day close
T+1d
+4.73%
call +4.73% · α +4.85%
$1.77
settled 3mo ago
T+5d
-2.37%
call -2.37% · α -1.38%
$1.65
settled 3mo ago
T+20d
-8.28%
call -8.28% · α -10.85%
$1.55
settled 2mo ago
T+60d
-31.95%
call -31.95% · α -36.20%
$1.15
settled 13d ago

Price Chart

Loading chart...

Executive Summary

Zeo ScientifiX issued a press release highlighting its role in South Florida's regenerative medicine ecosystem, with initiatives in physician education, scientific collaboration, and biologic R&D from Nova Southeastern University's Center for Collaborative Research. No financial data, milestones, contracts, or regulatory events were disclosed — the filing is a routine corporate positioning update.

Key Facts

  • Press release dated July 21, 2026, discusses ZEOX's regenerative biologic research, development, physician Master Classes, and Medical Advisory Board expansion.
  • No revenue, earnings, guidance, product approvals, partnerships, or capital events were reported.
  • Company operates from Nova Southeastern University's Center for Collaborative Research in Davie, Florida.
  • Filing contains only forward-looking statements with no concrete financial or operational catalysts.

Financial Impact

Not specified

Risk Factors

  • No specific risk factors disclosed; clinical-stage biopharma carries inherent development and regulatory risk.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001829126-26-007689
Document: zeoscientifix_ex99-1.htm0001829126-26-007689
Document: 0001829126-26-007689-index-headers.html0001829126-26-007689
Document: 0001829126-26-007689-index.html0001829126-26-007689
Document: 0001829126-26-007689.txt0001829126-26-007689
14 reports for ZEOX
Performance horizon
67% Hit rate @ T+20 2 of 3 directional calls Went positive at some point 3 of 3 best @ T+20▲ +13.87%Apr 9, 2026
Filters
Rows
Reports for ZEOX — sortable, filterable
TypeNow
Oct 26, 2026
1d ago
8-K
NEUTRAL ★ 5/10
$1.48awaiting T+20—$1.37 (−7.43%)
Sep 15, 2026
6w ago
8-K
NEUTRAL ★ 2/10
$1.36 $1.15▼ −15.44%▼ −18.42%$1.37 (+0.74%)
Sep 1, 2026
8w ago
8-K
NEUTRAL ★ 2/10
$1.20 $1.39▲ +15.83%▲ +14.65%$1.37 (+14.17%)
Aug 4, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$1.40 $1.20▼ −14.16%▼ −12.93%$1.37 (−2.00%)
Jul 21, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$1.69 $1.55▼ −8.28%▼ −10.85%$1.37 (−18.93%)
Jul 8, 2026
15w ago
8-K
BULLISH ★ 5/10
$1.80 $1.40▼ −22.33%▼ −25.61%$1.37 (−23.89%)
Jul 1, 2026
16w ago
8-K
NEUTRAL ★ 1/10
$1.77 $1.65▼ −6.78%▼ −4.59%$1.37 (−22.60%)
Jun 16, 2026
19w ago
8-K
NEUTRAL ★ 2/10
$1.72 $1.94▲ +12.79%▲ +11.93%$1.37 (−20.35%)
Jun 9, 2026
20w ago
8-K
NEUTRAL ★ 2/10
$1.67 $1.80▲ +7.78%▲ +6.39%$1.37 (−17.96%)
May 27, 2026
21w ago
8-K
NEUTRAL ★ 2/10
$1.85 $1.70▼ −8.11%▼ −6.21%$1.37 (−25.95%)
Showing 10 of 14

US Market Status

Market Closed — Opens Wed (17h 23m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 21, 2026